Brainsway Ltd. (TASE:BRIN) reports positive
interim results in the clinical trial of its Deep TMS transcranial magnetic
stimulation device for the treatment of bipolar disorder on patients who did not
respond to any medications.
The findings are based on the interim report by
the chief researcher on the nine patients in the study at the Shalvata
Psychiatric Hospital in Israel. The effect of Deep TMS on the patients was
measured using different methods for measuring depression, such as the Hamilton
Depression Rating Scale (HDRS), and self questionnaires.
The study found that all the patients
responded positively to the treatment, compared with previous treatments using
antidepressants. There were no complaints or side effects, except for slight
headaches that some patients felt after the treatment and which quickly passed.
The chief researcher at Shalvata said that the study was the first evidence
that Deep TMS was an effective treatment for bipolar disorder, with the caveat
that this was only the beginning.
Brainsway also reported the results of a
study on the effectiveness and safety of the use of Deep TMS for the treatment
of major depression in cases where patients did not respond to medications.
These findings are based on a preliminary report by the chief researcher on 54
patients participating in the trial at Shalvata.
Published by Globes Israel business news - www.globes.co.il - on August 8, 2007
Tuesday, August 14, 2007
rTMS for Bipolar Disorder
An article about Brainsway and their trials on using rTMS for Bipolar disorder.